-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind Medicine reports higher nasal tissue retention for intranasal MEAI in ex vivo study

PUBT·07/16/2026 17:40:01
Listen to the news
Clearmind Medicine reports higher nasal tissue retention for intranasal MEAI in ex vivo study
  • Clearmind Medicine reported positive ex vivo retention results for an intranasal formulation of MEAI, supporting its development program for Alcohol Use Disorder.
  • Results have already been presented, showing the mucoadhesive formulation stayed associated with nasal tissue longer than a standard MEAI solution.
  • The company is positioning the intranasal approach to improve absorption consistency, a key step toward differentiated dosing for high-need indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-078630), on July 16, 2026, and is solely responsible for the information contained therein.